Skip to search formSkip to main contentSkip to account menu

refractory plasma cell neoplasm

Known as: Refractory Multiple Myeloma, Refractory Plasma Cell Myeloma, plasma cell neoplasm, refractory 
A plasma cell neoplasm that is resistant to treatment.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
3010Background: To test the safety and efficacy of the CAR T cell modality in relapsed/refractory multiple myeloma (MM), we have… 
2015
2015
![Graphic][1] Introduction : Daratumumab (DARA) is a human anti-CD38 IgG1κ monoclonal antibody that showed synergistic anti… 
Highly Cited
2013
Highly Cited
2013
What is known and objective:  High costs of novel agents increasingly put pressure on limited healthcare budgets. Demonstration… 
Highly Cited
2012
Highly Cited
2012
DNA cross-linking agents are frequently used in the treatment of multiple myeloma–generating lesions, which activate checkpoint… 
Highly Cited
2011
Highly Cited
2011
Purpose: A phase I study was conducted to determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) for the… 
Highly Cited
2010
Highly Cited
2010
8032 Background: Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or relapsed/refractory… 
Highly Cited
2007
Highly Cited
2007
Thalidomide has direct antimyeloma and immunomodulatory effects. In addition, both thalidomide and metronomic chemotherapy… 
Highly Cited
2005
Highly Cited
2005
Bortezomib, a first‐in‐class proteasome inhibitor, is active with manageable toxicities in relapsed and/or refractory myeloma. 
Highly Cited
2002
Highly Cited
2002
INTRODUCTION Thalidomide has recently proven to be a useful drug for treatment of refractory and relapsed multiple myeloma… 
Highly Cited
2000